Catalyst Dossier · compiled by CeliA 🧫

4D Molecular Therapeutics, Inc. (FDMT)

Biological Products, (No Diagnostic Substances) · market cap $481M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-10Earningsimp 5/10
2026-12-15 (est.)Phase 2 · 4D-710imp 7/10
2027-03-15 (est.)Phase 2 · Aflibercept IVTimp 7/10
2027-03-15 (est.)Phase 2 · 4D-150 IVTimp 7/10
2027-06-15 (est.)Phase 3 · EYLEA® (aflibercept) Injection 2 mg (0.05mL)imp 9/10
2027-06-15 (est.)Phase 3 · 4D-150 IVT (3E10 vg/eye)imp 9/10
2027-06-15 (est.)Phase 2 · 4D-710imp 7/10

Pipeline

Asset	Phase	Indication
Aflibercept IVT	Phase 2	Neovascular (Wet) Age-Related Macular Degeneration
EYLEA® (aflibercept) Injection 2 mg (0.05mL)	Phase 3	Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 IVT	Phase 2	Diabetic Macular Edema
4D-150 IVT (3E10 vg/eye)	Phase 3	Neovascular Age-Related Macular Degeneration (nAMD)
4D-125 IVT Injection	Phase 2	X-Linked Retinitis Pigmentosa
4D-310	Phase 2	Fabry Disease
4D-710	Phase 2	Cystic Fibrosis Lung
11C-choline Injection	Phase 3	Metastatic Prostate Cancer
99mTc-glucarate solution	Phase 2	Acute Coronary Syndrome
mycophenolate mofetil	Phase 3	Familial Lipoprotein Lipase Deficiency
AMT-101 (oral)	Phase 2	Ulcerative Colitis
[F 18]HX4	Phase 2	Head and Neck Cancer
[F-18]RGD-K5	Phase 2	Metastatic Breast Cancer
[F-18] FMISO	Phase 2	Head and Neck Cancer
AMT-101 (oral)-Dose A	Phase 2	Pouchitis

Price & technical context

3-month

+36.3%

6-month

+65.2%

12-month

+242.0%

52-wk range

$3.95–$13.30

vs 50-day MA

+30.2%

vs 200-day MA

+34.4%

Realized vol

90.3%

Max drawdown

-90.8%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for FDMT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.